{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T08:48:47Z","timestamp":1792658927321,"version":"4.5.0"},"reference-count":25,"publisher":"American Academy of Pediatrics (AAP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,8,1]]},"abstract":"<jats:p>Objective. To characterize the type and frequency of biochemical lipid abnormalities and physical changes in body composition associated with the use of protease inhibitor (PI)-containing antiretroviral therapy among human immunodeficiency virus-infected children treated for up to 6 years.<\/jats:p>\n               <jats:p>Methods. A retrospective study of human immunodeficiency virus-infected pediatric patients enrolled in research protocols between August 1995 and December 2001 was performed. All patients who had received a PI for \u22652 years as part of their investigational antiretroviral treatment regimens during the study period were eligible. Of the 110 patients identified as having received PI therapy, 94 met the study criteria.<\/jats:p>\n               <jats:p>Results. Of the 94 patients evaluated, 9 patients (10%) developed fat redistribution as well as dyslipidemia, 49 patients (52%) developed dyslipidemia without associated physical changes, and 36 patients (38%) exhibited no elevation of lipid levels or physical signs of fat redistribution. For all 9 patients with fat redistribution, the onset of the physical changes was closely associated with changes during pubertal development. Fat redistribution was also associated with lower viral loads and higher, more sustained levels of dyslipidemia. The onset of dyslipidemia and fat redistribution peaked between 10 and 15 years of age.<\/jats:p>\n               <jats:p>Conclusion. Among pediatric patients receiving PI therapy, there seems to be an age range in which children are at greater risk of developing hypercholesterolemia and subsequent fat redistribution, suggesting that unidentified physiologic changes associated with puberty may predispose pediatric patients treated with PI therapy to developing lipodystrophy.<\/jats:p>","DOI":"10.1542\/peds.114.2.e235","type":"journal-article","created":{"date-parts":[[2004,8,14]],"date-time":"2004-08-14T00:53:04Z","timestamp":1092444784000},"page":"e235-e242","source":"Crossref","is-referenced-by-count":65,"title":["Natural History of Lipid Abnormalities and Fat Redistribution Among Human Immunodeficiency Virus-Infected Children Receiving Long-Term, Protease Inhibitor-Containing, Highly Active Antiretroviral Therapy Regimens"],"prefix":"10.1542","volume":"114","author":[{"given":"Perdita","family":"Taylor","sequence":"first","affiliation":[{"name":"Pediatric HIV Working Group, HIV and AIDS Malignancy Branch, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Worrell","sequence":"additional","affiliation":[{"name":"Pediatric HIV Working Group, HIV and AIDS Malignancy Branch, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth M.","family":"Steinberg","sequence":"additional","affiliation":[{"name":"Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Hazra","sequence":"additional","affiliation":[{"name":"Pediatric HIV Working Group, HIV and AIDS Malignancy Branch, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley","family":"Jankelevich","sequence":"additional","affiliation":[{"name":"Pediatric HIV Working Group, HIV and AIDS Malignancy Branch, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren V.","family":"Wood","sequence":"additional","affiliation":[{"name":"Pediatric HIV Working Group, HIV and AIDS Malignancy Branch, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheryl","family":"Zwerski","sequence":"additional","affiliation":[{"name":"Pediatric HIV Working Group, HIV and AIDS Malignancy Branch, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Yarchoan","sequence":"additional","affiliation":[{"name":"Pediatric HIV Working Group, HIV and AIDS Malignancy Branch, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Zeichner","sequence":"additional","affiliation":[{"name":"Pediatric HIV Working Group, HIV and AIDS Malignancy Branch, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2004,8,1]]},"reference":[{"key":"2021121006435395500_R1","doi-asserted-by":"crossref","unstructured":"Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection: HIV Outpatient Study Investigators. N Engl J Med.1998;338:853\u2013860","DOI":"10.1056\/NEJM199803263381301"},{"key":"2021121006435395500_R2","doi-asserted-by":"crossref","unstructured":"Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet.1999;353:2093\u20132099","DOI":"10.1016\/S0140-6736(98)08468-2"},{"key":"2021121006435395500_R3","doi-asserted-by":"crossref","unstructured":"Heath KV, Hogg RS, Chan KJ, et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV\/AIDS treatment database. AIDS.2001;15:231\u2013239","DOI":"10.1097\/00002030-200101260-00013"},{"key":"2021121006435395500_R4","doi-asserted-by":"crossref","unstructured":"Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS.1999;13:2493\u20132505","DOI":"10.1097\/00002030-199912240-00002"},{"key":"2021121006435395500_R5","doi-asserted-by":"crossref","unstructured":"Mauss S, Corzillius M, Wolf E, et al. Risk factors for the HIV-associated lipodystrophy syndrome in a closed cohort of patients after 3 years of antiretroviral treatment. HIV Med.2002;3:49\u201355","DOI":"10.1046\/j.1464-2662.2001.00100.x"},{"key":"2021121006435395500_R6","doi-asserted-by":"crossref","unstructured":"Shevitz A, Wanke CA, Falutz J, Kotler DP. Clinical perspectives on HIV-associated lipodystrophy syndrome: an update. AIDS.2001;15:1917\u20131930","DOI":"10.1097\/00002030-200110190-00003"},{"key":"2021121006435395500_R7","unstructured":"Mauss S. HIV-associated lipodystrophy syndrome. AIDS.2000;14 (suppl 3):S197\u2013S207"},{"key":"2021121006435395500_R8","doi-asserted-by":"crossref","unstructured":"Yanovski JA, Miller KD, Kino T, et al. Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy. J Clin Endocrinol Metab.1999;84:1925\u20131931","DOI":"10.1210\/jcem.84.6.5740"},{"key":"2021121006435395500_R9","doi-asserted-by":"crossref","unstructured":"Jaquet D, Levine M, Ortega-Rodriguez E, et al. Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children. AIDS.2000;14:2123\u20132128","DOI":"10.1097\/00002030-200009290-00008"},{"key":"2021121006435395500_R10","doi-asserted-by":"crossref","unstructured":"Melvin AJ, Lennon S, Mohan KM, Purnell JQ. Metabolic abnormalities in HIV type 1-infected children treated and not treated with protease inhibitors. AIDS Res Hum Retroviruses.2001;17:1117\u20131123","DOI":"10.1089\/088922201316912727"},{"key":"2021121006435395500_R11","doi-asserted-by":"crossref","unstructured":"Arpadi SM, Cuff PA, Horlick M, Wang J, Kotler DP. Lipodystrophy in HIV-infected children is associated with high viral load and low CD4+-lymphocyte count and CD4+-lymphocyte percentage at baseline and use of protease inhibitors and stavudine. J Acquir Immune Defic Syndr.2001;27:30\u201334","DOI":"10.1097\/00042560-200105010-00005"},{"key":"2021121006435395500_R12","doi-asserted-by":"crossref","unstructured":"Wedekind CA, Pugatch D. Lipodystrophy syndrome in children infected with human immunodeficiency virus. Pharmacotherapy.2001;21:861\u2013866","DOI":"10.1592\/phco.21.9.861.34555"},{"key":"2021121006435395500_R13","doi-asserted-by":"crossref","unstructured":"Brambilla P, Bricalli D, Sala N, et al. Highly active antiretroviral-treated HIV-infected children show fat distribution changes even in absence of lipodystrophy. AIDS.2001;15:2415\u20132422","DOI":"10.1097\/00002030-200112070-00009"},{"key":"2021121006435395500_R14","doi-asserted-by":"crossref","unstructured":"Cheseaux JJ, Jotterand V, Aebi C, et al. Hyperlipidemia in HIV-infected children treated with protease inhibitors: relevance for cardiovascular diseases. J Acquir Immune Defic Syndr.2002;30:288\u2013293","DOI":"10.1097\/00126334-200207010-00004"},{"key":"2021121006435395500_R15","unstructured":"National Institutes of Health. National Cholesterol Education Program, ATP III Guidelines At-A-Glance Quick Desk Reference. Bethesda, MD: National Heart, Lung, and Blood Institute; 2001"},{"key":"2021121006435395500_R16","doi-asserted-by":"crossref","unstructured":"Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc.1958;53:457\u2013481","DOI":"10.1080\/01621459.1958.10501452"},{"key":"2021121006435395500_R17","unstructured":"Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chem Rep.1966;50:163\u2013170"},{"key":"2021121006435395500_R18","doi-asserted-by":"crossref","unstructured":"Rakotoambinina B, Medioni J, Rabian C, Jubault V, Jais JP, Viard JP. Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor. J Acquir Immune Defic Syndr.2001;27:443\u2013449","DOI":"10.1097\/00042560-200108150-00004"},{"key":"2021121006435395500_R19","doi-asserted-by":"crossref","unstructured":"Wanke CA, Falutz JM, Shevitz A, Phair JP, Kotler DP. Clinical evaluation and management of metabolic and morphologic abnormalities associated with human immunodeficiency virus. Clin Infect Dis.2002;34:248\u2013259","DOI":"10.1086\/324744"},{"key":"2021121006435395500_R20","doi-asserted-by":"crossref","unstructured":"Dube M, Fenton M. Lipid abnormalities. Clin Infect Dis.2003;36 (suppl 2):S79\u2013S83","DOI":"10.1086\/367562"},{"key":"2021121006435395500_R21","doi-asserted-by":"crossref","unstructured":"Vigano A, Mora S, Testolin C, et al. Increased lipodystrophy is associated with increased exposure to highly active antiretroviral therapy in HIV-infected children. J Acquir Immune Defic Syndr.2003;32:482\u2013489","DOI":"10.1097\/00126334-200304150-00003"},{"key":"2021121006435395500_R22","doi-asserted-by":"crossref","unstructured":"Power R, Tate HL, McGill SM, Taylor C. A qualitative study of the psychosocial implications of lipodystrophy syndrome on HIV positive individuals. Sex Transm Infect.2003;79:137\u2013141","DOI":"10.1136\/sti.79.2.137"},{"key":"2021121006435395500_R23","doi-asserted-by":"crossref","unstructured":"Stein JH, Klein MA, Bellehumeur JL, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation.2001;104:257\u2013262","DOI":"10.1161\/01.CIR.104.3.257"},{"key":"2021121006435395500_R24","doi-asserted-by":"crossref","unstructured":"Lewis W. Atherosclerosis in AIDS: potential pathogenetic roles of antiretroviral therapy and HIV. J Mol Cell Cardiol.2000;32:2115\u20132129","DOI":"10.1006\/jmcc.2000.1271"},{"key":"2021121006435395500_R25","doi-asserted-by":"crossref","unstructured":"Hadigan C, Meigs JB, Wilson PW, et al. Prediction of coronary heart disease risk in HIV-infected patients with fat redistribution. Clin Infect Dis.2003;36:909\u2013916","DOI":"10.1086\/368185"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/114\/2\/e235\/1017120\/zpe0080400e235.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/114\/2\/e235\/1017120\/zpe0080400e235.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T15:30:11Z","timestamp":1639150211000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/114\/2\/e235\/64621\/Natural-History-of-Lipid-Abnormalities-and-Fat"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8,1]]},"references-count":25,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2004,8,1]]},"published-print":{"date-parts":[[2004,8,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.114.2.e235","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,8,1]]}}}